---
title: 'Director, Program Management at Summit Therapeutics'
canonical: 'https://feeny.ai/job/director-program-management-summit-therapeutics-palo-alto-dynh3a9xrr1d'
type: 'job'
last_seen: '2026-10-16'
---

# Director, Program Management at Summit Therapeutics

- **Company:** Summit Therapeutics
- **Location:** Palo Alto, CA
- **Compensation:** $190k–$237k
- **Posted:** 2026-08-19
- **Last confirmed live:** 2026-10-16
- **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4371691009

## Job description

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

- HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

- HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

- HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

- HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

## Our Mission

To build a viable long-lasting health care organization that assumes full responsibility for designing, developing, trial enrollment, regulatory approval and commercializing patient, physician, caregiver, payor, and societal friendly medicinal therapy intended to improve quality of life, increase potential duration of life and resolve serious medical healthcare needs. We will accomplish this by building a team of world-class scientists and business administrators that apply themselves to this mission.

We have in-licensed Ivonescimab (PD-1/VEGF Bispecific Antibody, SMT112), which is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. We have ongoing phase-III clinical studies in multiple indications including NSCLC and CRC.

## Overview

The Director of Program Management provides strategic and operational leadership across multiple development programs, driving alignment between Research, Development, Business Strategy, Manufacturing, and execution.  This role plays a critical part in advancing collaboration programs across the portfolio and enabling long-term value creation from development through regulatory approval.

The Director serves as the primary point of contact for key programs to executive leadership, ensures disciplined program governance, and strengthens the Program Management function as the organization scales. This position reports to the VP, Program Management and may have people leadership responsibility.

## Role and Responsibilities

Strategic Program Leadership

- Responsible for overall execution of multiple programs to deliver on program objectives and maximize value.
- Partner with executive leadership on program, strategy,
- Define and oversee major milestones, decision points, objectives, and inflection points across programs
- Lead scenario planning, trade-off analyses, and decision frameworks to support executive decision-making
- Ensure alignment across Development, Regulatory, Manufacturing, and Corporate Strategy

Cross-Functional & Executive Leadership

- Lead and integrate complex cross-functional workstreams across Research, Development, Regulatory, and Manufacturing
- Facilitate effective decision-making and accountability across global teams and external partners, in collaboration with Alliance Management.
- Present clear insights, recommendations, and program status to C-suite and senior leadership
- Mentor and develop Program Managers and strengthen organizational capability

Program Execution & Governance

- Oversee end-to-end program execution, including activation of new indications post–Go decision
- Ensure consistent application of program management standards, dashboards, and governance models
- Chair timely, efficient, and action-oriented team meetings to coordinate operations and communications.
- Review and validate integrated program plans, timelines, and metrics for accuracy and strategic alignment
- Represent Program Management on senior governance forums and key internal or external teams

Timelines & Scenario Planning

- Oversee integrated program timelines aligned with enterprise goals
- Partner with functional leaders on budgets and forecast planning
- Ensure data integrity and transparency in executive reporting

Risk, Opportunity & Continuous Improvement

- Identify and manage program risks and mitigation strategies
- Communicate risks, opportunities, and trade-off s clearly to executive leadership
- Drive continuous improvement of program management processes, tools, and operating models
- Lead strategic initiatives to mature the Program Management function as the company grows
- All other duties as assigned

## Experience, Education and Specialized Knowledge

- Bachelor’s degree and minimum 12 years of relevant project management/scientific experience within the pharmaceutical industry; OR a MS or MBA and minimal 10 years of relevant experience; OR a PhD in a scientific field or a PharmD, DVM or MD degree with 6+ years of relevant experience
- 10–12+ years of pharmaceutical or biotech industry experience with progressive responsibility in program or portfolio management
- Extensive pharmaceutical drug development experience required;
- Prior solid tumor oncology experience, including late-stage development and registrational trials, required
- Demonstrated success leading complex, global, cross-functional programs and influencing senior executives
- Experience with managing alliances and external partners strongly preferred
- Proven ability to balance strategic leadership with operational execution
- Exceptional communication, facilitation, and presentation skills
- Strong proficiency in program management and planning tools (e.g., MS Office, Project, Smartsheet)
- Willing to travel for key meetings.

This is the pay for this position

Pay Transparency $190,000—$237,000 USD

Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.

Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.

## About Summit Therapeutics

## Company Overview
- **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors.
- **Entity Type**: Public (NASDAQ: SMMT)
- **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland)
- **Founded**: 2003
- **Founders**: Not publicly disclosed on the company website; the company was founded in 2003.

## Core Business
- **Primary industry**: Biopharmaceuticals / Oncology
- **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology
- **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx)

## Products & Services
- **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx)

## Market Standing
- **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics)
- **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings.
- **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors.
- **Growth Signals**: 
  - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics)
  - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE).
  - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx)
  - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx)

## Competitive Advantages
- **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies.
- **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials.
- **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world.
- **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline.

## Strategic Focus
- **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization.
- **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player.
- **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure.

## Why Work Here
- **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx)
- **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives."
- **Benefits (U.S.)**: 
  - 401(k) with 6% employer match
  - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit
  - Flexible Spending Account
  - Commuter Benefit
  - Onsite lunch provided
- **Benefits (U.K.)**: 
  - Private Medical Insurance
  - Employee Assistance Program
  - Life Assurance Policy
  - Company Pension Contributions
  - ESPP
- **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles.
- **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics)
- **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement.

## Sources
1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx)
2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx)
3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx)
4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx)
5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics)
6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics)

## Other roles at Summit Therapeutics

- [Senior Principal Scientist](https://feeny.ai/job/senior-principal-scientist-summit-therapeutics-palo-alto-n0strqh510r6) — Palo Alto, CA
- [Associate Director, Clinical Supply Management (UK/EU)](https://feeny.ai/job/associate-director-clinical-supply-management-uk-eu-summit-therapeutics-oxford-4hve8zj7pay9) — Oxford UK Zug Switzerland Dublin, Ireland
- [Director, Sourcing & Procurement - R&D Clinical Operations and Supplies](https://feeny.ai/job/director-sourcing-procurement-r-d-clinical-operations-and-supplies-summit-1ctpcgpnyv4w) — United States
- [Associate Director, Clinical Supply Management](https://feeny.ai/job/associate-director-clinical-supply-management-summit-therapeutics-princeton-nj-mvc6azpxcvpd) — Princeton NJ US and Palo Alto CA, United States
- [Regional Marketing Director](https://feeny.ai/job/regional-marketing-director-summit-therapeutics-princeton-p443zfx10fsb) — Princeton, NJ
- [Director, Clinical Scientist](https://feeny.ai/job/director-clinical-scientist-summit-therapeutics-united-states-4b7fcrb9mkfb) — United States
- [Senior Medical Director](https://feeny.ai/job/senior-medical-director-summit-therapeutics-united-states-6d943xf75bpx) — United States
- [Senior Director, Oncology Clinical Educators](https://feeny.ai/job/senior-director-oncology-clinical-educators-summit-therapeutics-field-8pyx53adkr7g) — Field, United States
- [Director, Clinical Operations Analytics & Performance Excellence](https://feeny.ai/job/director-clinical-operations-analytics-performance-excellence-summit-wqz1bgajvnrd)
- [Corporate Counsel, Clinical Contracts](https://feeny.ai/job/corporate-counsel-clinical-contracts-summit-therapeutics-united-states-kr3cyb13nj9c) — United States